T36.7X6D Underdosing of antifungal antibiotics, systemically used, subsequent encounter

Name of the Condition

• Underdosing of antifungal antibiotics, systemically used, subsequent encounter

Summary

This condition describes underdosing of systemically administered antifungal antibiotics during a subsequent encounter. It applies when therapeutic levels are not achieved due to insufficient dosing, non-adherence, or prescription errors, and the patient is receiving ongoing care for this issue. Documentation should specify the antifungal agent, the reason for underdosing, and details of the subsequent encounter.

Causes

Underdosing may result from dosing errors, patient non-adherence, inadequate prescription, or altered drug absorption/metabolism. It can occur due to miscommunication between providers and patients, changes in renal or hepatic function affecting drug clearance, or failure to adjust doses for weight, age, or comorbidities.

Risk Factors

• Prior history of medication non-adherence.
• Renal or hepatic impairment altering drug metabolism.
• Pediatric or geriatric populations with variable pharmacokinetics.
• Polypharmacy increasing dosing complexity.
• Inadequate patient education on proper administration.

Symptoms

• Persistent or worsening infection signs (e.g., fever, localized pain).
• Delayed treatment response or therapeutic failure.
• Recurrence of fungal infection symptoms.
• Subtherapeutic drug levels on monitoring (if tested).

Diagnosis

Diagnosis involves clinical assessment of treatment failure, review of medication history, and verification of dosing adequacy. Therapeutic drug monitoring (if applicable) may confirm subtherapeutic levels. Underlying causes (e.g., non-adherence, metabolic changes) are investigated to guide management.

Treatment Options

Treatment focuses on correcting the underdosing: adjusting the antifungal dose, improving adherence (e.g., education, simplified regimens), or addressing barriers to proper administration. In some cases, switching to a more suitable antifungal or optimizing supportive care may be necessary.

Prognosis and Follow-Up

Prognosis depends on the severity of underdosing and the underlying infection. Timely correction typically improves outcomes, but delayed intervention may lead to treatment failure or complications. Follow-up includes monitoring for clinical response, drug levels (if indicated), and addressing adherence issues.

Complications

• Worsening or disseminated fungal infection.
• Increased risk of antifungal resistance.
• Prolonged illness or hospitalization.
• Potential for additional interventions (e.g., higher-dose therapy, combination treatment).

Lifestyle & Prevention

• Ensure clear communication about dosing schedules and importance of adherence.
• Use pill organizers or reminders for complex regimens.
• Address barriers to adherence (e.g., cost, side effects) with providers.
• Regularly review medication lists with healthcare teams to avoid errors.

When to Seek Professional Help

Seek care if infection symptoms worsen, new symptoms develop, or treatment appears ineffective. Prompt evaluation is needed to assess for underdosing, adjust therapy, or rule out other causes of treatment failure.

Tips for Medical Coders

Code T36.7X6D is used for subsequent encounters related to underdosing of systemically used antifungal antibiotics. Document the specific antifungal agent, reason for underdosing (e.g., non-adherence, dosing error), and encounter context (subsequent) to support accurate coding. Ensure differentiation from initial encounters or other poisoning/adverse effect codes.